logo

Synthetic Biologics Inc. (SYN)



Trade SYN now with
  Date
  Headline
12/5/2017 8:06:12 AM Synthetic Biologics Names Steve Shallcross Interim CEO, To Succeed Jeff Riley
5/11/2017 7:16:25 AM Synthetic Biologics Says SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation From FDA
1/5/2017 6:59:24 AM Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection
12/13/2016 6:59:52 AM Synthetic Reports Granting Of Composition Of Matter Patent For SYN-005, Designed For Treatment & Prevention Of Pertussis
11/1/2016 7:17:19 AM Synthetic Biologics Q3 Loss/shr Narrows To $0.09 From $0.12 Last Year
10/6/2016 7:06:15 AM Synthetic Biologics Awarded Research Contract From CDC For Microbiome Assessment And Intervention
9/20/2016 7:09:54 AM Synthetic Biologics Completes Enrollment For Phase 2b Proof-of-Concept Clinical Trial For SYN-004
7/12/2016 7:00:43 AM Synthetic Biologics Secures European And U.S. Composition Of Matter Patents For Ribaxamase
7/7/2016 6:58:51 AM Synthetic Biologics Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004
5/23/2016 6:53:13 AM Synthetic Biologics Announces Data From Two SYN-010 Phase 2 Trials For Treatment Of IBS-C
5/16/2016 6:59:43 AM Synthetic Reports Positive Results From IInd Phase 2a Trial Of SYN-004 For Prevention Of C. Difficile Infection And AAD
5/11/2016 6:58:47 AM Isaac Bright Joins Synthetic Biologics As VP Corporate Development
5/9/2016 6:58:55 AM Synthetic Biologics Appoints Deb Mathews VP, Medical Affairs
2/29/2016 4:13:12 PM Intrexon Q4 Loss Per Share $0.28 Vs. EPS Of $0.18 Last Year
2/17/2016 7:00:36 AM Synthetic Biologics Reports Allowance Of Key U.S. Patent Covering SYN-010
2/2/2016 7:00:15 AM Synthetic Biologics To Terminate License And Trial Deal Relating To Trimesta With Regents Of University Of California
  
 
>